International Clinical and Medical Case Reports Journal (ISSN: 2832-5788) | Volume 3, Issue 12 | Research Article | Open Access DOI
Prayas Sethi*
Manraj Singh Sra, MBBS1, Prayas Sethi, MD1*, Amulya Gupta, MBBS1, Mehak Arora, MBBS1, Shivam Pandey, PhD2, Ved Prakash Meena, MD1, Animesh Ray, MD1, Arvind Kumar, MD1, Vineeta Venkateswaran, MD3, Akhil Kant Singh, MD3, Yudhyavir Singh, MD3, Puneet Khanna, MD3, Naveet Wig, MD1
1Department of Medicine, All India Institute of Medical Sciences, New Delhi
2Department of Biostatistics, All India Institute of Medical Sciences, New Delhi
3Department of Anaesthesiology, Pain Medicine and Critical Care, All India Institute of Medical Sciences, New Delhi
*Correspondence to: Prayas Sethi
Fulltext PDFBackground: Newly diagnosed diabetes mellitus (DM) and worsening of pre-existing DM have been an important consideration during post-COVID care. However, definitive follow-up studies are lacking. We aimed to assess serial changes in glycemic control of patients with DM up to 6 months post-COVID-19 infection in this pilot study.
Methods: Patients with DM, aged ≥18 years with laboratory-confirmed SARS-CoV2 infection were enrolled in this study. The fasting and post-prandial blood glucose levels before COVID-19 infection and 1, 3 and 6 months post-COVID-19 infection were compared.
Results:Among 31 patients completing the follow-up, transient and persistent dysglycemia was seen in 10 (32.2%) and 4 (12.9%) patients, respectively. No significant change was observed in fasting (p=0.845) and post-prandial (p=0.0725) blood glucose levels over 6 months.
Conclusion: No significant changes in glycemic control are observed post-COVID-19 in patients with DM. Transient dysglycemia due to critical illness and corticosteroid use, and withdrawal of insulin during post-COVID-19 follow-up has been observed. Aggressive treatment for glycemic control has also been a factor for better glycemic outcomes and hence no significant overall effect. However, in view of a few patients demonstrating a persistent worsening of glycemic control even in the absence of steroid use or months after use in mild disease, close monitoring of blood sugar is advisable during follow-up. Large-scale studies with robust follow-up may be required in this regard.
COVID-19; Diabetes Mellitus; Post-COVID-19 infection; Post-COVID-19 dysglycemia
Manraj Singh Sr, Prayas Sethi, Amulya Gupta, Mehak Arora, Shivam Pandey, Ved Prakash Meena, et al. Variation in Glycemic Control Post-COVID-19 in Patients with Diabetes Mellitus: A Pilot Study. Int Clinc Med Case Rep Jour. 2024;3(12):1-11.